On August 24, 2026, the Genetic Literacy Project published a viewpoint calling the FDA's reconstituted Pharmacy Compounding Advisory Committee a roster of "physician grifters" who legitimized a "cure-all peptides craze." The charge lands one month after the panel's July 23–24 meeting, where members overruled the agency's career scientists six separate times to recommend BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for the Section 503A Bulks List. Placement on that registry would allow state-licensed pharmacies to compound the substances for individual prescriptions. Several of the voting members operate clinics that sell or prescribe those same peptides, a financial overlap the viewpoint's authors argue no standard ethics clearance resolves.
The recommendation is advisory. Health and Human Services Secretary Robert F. Kennedy Jr., who has called himself a "big fan" of peptides and vowed to overturn restrictions imposed under the prior administration, has not directed the FDA to act. The agency told The Guardian it is "considering the pharmacy compounding advisory committee's recommendations" and will consult the United States Pharmacopeia before issuing a determination.
The vote and the science it set aside
In the first ballot on July 23, the panel voted 8 to 6, with one abstention, to recommend BPC-157 for the Bulks List. Five additional peptides passed by similarly narrow margins. FDA staff scientists had briefed the committee with materials concluding that the five clinical trials of BPC-157 were short in duration, small in sample size, and insufficient to establish safety or effectiveness. For TB-500, regulators identified no completed human studies. AJMC's account of the reversal notes the advisers backed all six peptides despite those findings and despite persistent gray-market risks. The panel's single rejection fell on emideltide, or delta sleep-inducing peptide, which failed 7 to 6 with one abstention.
Before the meeting, more than a half-dozen people with ties to the peptide industry were added to the committee, including doctors, pharmacists, and consultants working in the field. AP News reporting documented the roster changes and recorded David Pope, chief pharmacy officer of Xifin Pharmacy Solutions, saying after the BPC-157 vote: "I voted yes because it's time to put this decision back in the hands of the patient, the physician and the pharmacist." HHS responded to composition concerns by stating that all members underwent "the same ethics review and vetting process required of all FDA advisory committee members." The Genetic Literacy Project's authors counter that formal clearance does not address the structural problem of market participants voting to expand the markets in which they earn revenue.
Celebrity demand and the pending determination
The consumer market driving interest in these substances is anchored in podcast and social-media promotion rather than peer-reviewed evidence. Joe Rogan has said BPC-157 eliminated his elbow tendinitis within two weeks and has repeatedly paired it with TB-500 under the nickname the wolverine stack peptide. Actor Josh Duhamel has described using the same combination. Hailey Bieber has promoted BPC-157 for gut health and muscle recovery. Both BPC-157 and TB-500 remain classified as doping substances by international sports authorities and continue to circulate online under "research use only" disclaimers despite FDA restrictions imposed in 2023.
Determining whether peptides are legal hinges on the specific regulatory pathway invoked. A 503A Bulks List placement would create a prescription compounding channel without granting any of the six substances the status of FDA-approved peptides. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, noted after the meeting that the agency must still formally adopt the advisers' recommendations before pharmacies may legally compound the substances. Kennedy could seek to expedite that adoption, though experts say the procedural path and timeline remain unclear.
The FDA's stated next step is its consultation with the United States Pharmacopeia on whether the six peptides meet the agency's criteria for the Bulks List. No date for that consultation has been publicly scheduled. Until the commissioner issues a final order following the USP review, the July votes remain advisory, and the peptides remain barred from legal compounding.
